Edward B. Garon
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 166
- Cancer Immunotherapy and Biomarkers 109
- Colorectal Cancer Treatments and Studies 30
- Lung Cancer Research Studies 27
- CAR-T cell therapy research 12
-
- Lung Cancer Treatments and Mutations 123
- Lung Cancer Diagnosis and Treatment 25
- Co-authors
- Enriqueta Felip (28 shared papers)Roy S. Herbst (17 shared papers)Gregory M. Lubiniecki (12 shared papers)Myung‐Ju Ahn (12 shared papers)Ji‐Youn Han (9 shared papers)Margarita Majem Tarruella (8 shared papers)Jose Luis Perez-Gracia (5 shared papers)Catherine Dubos Arvis (6 shared papers)
- Journals
- Journal of Thoracic Oncology (50 papers)Annals of Oncology (38 papers)Lung Cancer (16 papers)Clinical Lung Cancer (13 papers)Clinical Cancer Research (13 papers)
- Partner nations
- United StatesGermanySpain
In The Last Decade
Edward B. Garon
277 papers receiving 42.5k citations
Edward B. Garon's Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 26.9k
- Pulmonary and Respiratory Medicine 15.0k
- Immunology 7.8k
- Cancer Research 5.1k
- Pathology and Forensic Medicine 1.7k
Countries citing papers authored by Edward B. Garon
This map shows the geographic impact of Edward B. Garon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward B. Garon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward B. Garon more than expected).
Fields of papers citing papers by Edward B. Garon
This network shows the impact of papers produced by Edward B. Garon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward B. Garon. The network helps show where Edward B. Garon may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward B. Garon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 290 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Hit paper breakdown → | 2015 | 6617 |
| 2 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Hit paper breakdown → | 2015 | 5515 |
| 3 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 5263 |
| 4 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 5249 |
| 5 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Hit paper breakdown → | 2014 | 1428 |
| 6 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1049 |
| 7 | Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial Hit paper breakdown → | 2017 | 906 |
| 8 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 892 |
| 9 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 842 |
| 10 | Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 732 |
| 11 | Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 595 |
| 12 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer Hit paper breakdown → | 2020 | 526 |
| 13 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 492 |
| 14 | Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer Hit paper breakdown → | 2012 | 483 |
| 15 | A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC Hit paper breakdown → | 2018 | 476 |
| 16 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Hit paper breakdown → | 2017 | 469 |
| 17 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Hit paper breakdown → | 2023 | 436 |
| 18 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study Hit paper breakdown → | 2022 | 328 |
| 19 | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Hit paper breakdown → | 2021 | 323 |
| 20 | 2013 | 314 |
About Edward B. Garon
Edward B. Garon is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 290 papers that have together received 43.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (123 papers), Cancer Immunotherapy and Biomarkers (109 papers), Colorectal Cancer Treatments and Studies (30 papers), Cancer Genomics and Diagnostics (28 papers), Lung Cancer Research Studies (27 papers), Lung Cancer Diagnosis and Treatment (25 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (12 papers). The work is most often cited by research in Oncology (26.9k citations), Pulmonary and Respiratory Medicine (15.0k citations), Immunology (7.8k citations), Cancer Research (5.1k citations) and Pathology and Forensic Medicine (1.7k citations). Edward B. Garon has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Enriqueta Felip, Roy S. Herbst, Gregory M. Lubiniecki, Myung‐Ju Ahn, Ji‐Youn Han, Margarita Majem Tarruella, Jose Luis Perez-Gracia, Catherine Dubos Arvis, Dong‐Wan Kim and Gilberto de Castro Junior. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer, Clinical Lung Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.